of periradicular lesions (16, 17) , and presented evidence suggesting that MMP-13 plays a potentially unique physiological role in wound healing and regeneration of alveolar bone. Because alveolar bone tissue consists predominantly of osteoblasts, these cells may represent a potential target cell type for new therapeutic strategies to mitigate these disease states. Moreover, we have reported that the proinflammatory cytokine interleukin (IL)-1 induces MMP-13 activity in purified osteoblastlike cells derived from human stem cells (16, 17) .
Mesenchymal stem cells (MSCs) are multipotent cells in bone marrow and various other tissues, which are capable of differentiating into osteogenic cells, especially osteoblasts, as well as chondrogenic and adipogenic lineages by culturing in appropriate in vitro conditions (18) . MSCs have been identified in adipose tissue, which are termed adipose tissue-derived MSCs (AT-MSCs) (19) (20) (21) . Compared with bone marrowderived MSCs (BMSCs), human AT-MSCs are easier to obtain, have relatively lower donor site morbidity, a higher yield at harvest, and can expand more rapidly in vitro than BMSCs (22, 23) . Moreover, the proliferation and differentiation potential of AT-MSCs are independent of age (24, 25) . Under appropriate conditions, AT-MSCs can be induced into an osteogenic lineage in vitro and can therefore be seeded in proper scaffolds as seed cells to repair bone defects. These advantages suggest that human AT-MSCs are a promising alternative source of seed cells for tissue engineering and regeneration.
We recently established a differentiation method for homogeneous α7 integrin-positive human skeletal muscle stem cell-derived osteoblast-like cells (26) , and found that IL-1β induces MMP-13-regulated proliferation of these cells (16, 17) . These data suggest that MMP-13 plays a potentially unique physiological role in the regeneration of osteoblastlike cells. We previously reported that Poly(P) induces MMP-3-mediated proliferation of odontoblast-like cells derived from mouse induced pluripotent stem cells (9) . Although it is known that Poly(P) induces differentiation of osteoblastic cells, the detailed mechanism of Poly(P)-induced differentiation in ATMSCs remains to be elucidated.
In the current study, we employed purified osteoblast-like cells derived from human AT-MSCs (hAT-MSCs) as an appropriate cell model to examine the mechanism of Poly(P)-induced differentiation in vitro. We show, for the first time, that Poly(P)-induced MMP-13 regulates differentiation of osteoblast-like cells from hAT-MSCs.
Materials and Methods

Materials
Type-65 Poly(P) with an average chain length of 65 phosphate residues was prepared from sodium tripolyphosphate (Taihei Chemical Industrial Co., Ltd., Osaka, Japan). Concentrations of Poly(P) are shown in terms of phosphate residues (27) . As a control, sodium phosphate buffer (pH 6.9) was used instead of Poly(P).
Cell culture
hAT-MSCs were obtained from Takara Bio Inc. (Shiga, Japan) and grown in growth medium (C-28010; Takara Bio Inc.) according to the manufacturer's protocols. hAT-MSCs were tested for cell morphology, proliferation potential, adherence rate, and viability. Furthermore, they were characterized by flow cytometric analysis of a comprehensive panel of markers, namely CD73, CD90, CD105, CD14, CD19, CD34, and CD45 (28) . Adipogenic, osteogenic and chondrogenic differentiation assays were performed under each appropriate culture condition without antibiotics or antimycotics. Passage 6-9 cells were used in experiments. At 70% confluence, the medium was replaced with osteogenic differentiation medium (ODM) (C-28013; Takara Bio Inc.) or growth medium every 3 days up to 21 days. The first day the medium was replaced with osteogenic culture medium was defined as day 0.
Cell proliferation assay and microscopic analysis
Cell proliferation was evaluated using a bromodeoxyuridine (BrdU)-cell proliferation enzyme-linked immunosorbent assay (ELISA; Roche Applied Science, Mannheim, Germany) as described previously (29, 30) . In addition, cell proliferation was evaluated visually under a BZ-9000 microscope (Keyence, Osaka, Japan) using a BrdU immunohistochemistry kit (Abcam, Cambridge, UK) according to the manufacturer's instructions.
Functional assay for assessment of the osteogenic phenotype
To assess the phenotype of cultured cells, we measured ALP activity and calcification as markers of differentiation. ALP activity was determined using an ALP Staining Kit (Primary Cell Co., Ltd., Hokkaido, Japan). Mineralization from the Poly(P)-treated cells was quantified using an Alizarin red S (ARS) assay (Sigma-Aldrich, St. Louis, MO, USA). ARS staining was quantified using a previously reported method (31) and photographed under the BZ-9000 microscope and/ or an IN Cell Analyzer 2000 (GE Healthcare UK Ltd., Buckinghamshire, England).
Real-time quantitative reverse transcriptionpolymerase chain reaction (qRT-PCR) analysis
qRT-PCR was performed on all samples and standards Whitney U-test. A p-value of less than 0.05 was considered statistically significant.
Results
Poly(P) alters hAT-MSC proliferation
We first analyzed the effect of Poly(P) on the cell proliferation of hAT-MSCs using the BrdU-cell proliferation ELISA. As a result, we found that Poly(P) increased cell proliferation in a dose-independent manner. Poly(P) at a concentration of 0.2 mM was optimal to enhance cell growth (p < 0.05) ( Figure  1 ). Both 0.1 and 0.5 mM Poly(P) resulted in potent inhibition of cell proliferation.
Poly(P) induces osteogenic differentiation of hATMSCs
We previously analyzed the effect of Poly(P) on cell proliferation of rat DPFCs, and found that 0.2 mM Poly(P) is an optimal concentration to enhance the cell growth, whereas more or less than 0.2 mM Poly(P) results in potent inhibition of cell proliferation (10) .
To examine whether Poly(P) induced osteogenic characteristics in hAT-MSCs, the cells were cultured in the presence of 0.2 mM Poly(P) for 7 days. Both qRT-PCR and Western blotting revealed higher expression of osteogenic differentiation markers ALPL, BGLAP, SPP1, OSX, and BSP (Figure 2A-a, b) .
The majority of Poly(P)-treated hAT-MSCs showed strong ALP expression, whereas control cells had undetectable ALP expression ( Figure 2B-a, b) . Extensive deposits of calcified matrix were observed in Poly(P)-treated hAT-MSC cultures, whereas calcified matrix was not apparent in control cell cultures ( Figure  2C-a, b) . Consistently, Poly(P) treatment induced a marked increase in ARS signals ( Figure 2C-a, 
Western blot analysis
Cells were cultured for 6 h with or without Poly(P) and then lysed using cell lysis buffer (Cell Signaling Technology Japan, K.K., Tokyo, Japan). Proteins were separated on 12% SDS-polyacrylamide gels for Western blot analysis using anti-ALP, -OC, -OP, -OSX, -BSP, -MMP-13 and -β-tubulin polyclonal antibodies (sc-271431, sc-30044, sc-10593, sc-22538, sc-73634, sc-30073, and sc-9935, respectively; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Visualization of blotted protein bands was performed using a Multi Gauge-Ver3.X (Fujifilm, Tokyo, Japan).
Measurement of MMP-13 activity
The protocol for measurement of MMP-13 activity has been described previously (32, 33) and is now a commercially available MMP-13 activity assay kit (SensoLyte™ 520 MMP-13 assay kit; AnaSpec, San Jose, CA, USA).
Silencing of the MMP-13 gene by small interfering RNA (siRNA) transfection
Commercially available MMP-13 siRNA (sc-41559, Santa Cruz Biotechnology, Inc.) was transfected into cultured cells using an siRNA reagent system (sc-45064, Santa Cruz Biotechnology, Inc.) according to the manufacturer's protocol. GAPDH siRNA and a control siRNA without known homology to any vertebrate sequence (Thermo Scientific, Lafayette, CO, USA) were used as positive and negative controls, respectively.
Statistical analysis
Data presented in bar graphs are the means ± standard deviation (SD) of four to six independent experiments. Statistical significance was assessed using the Mann- together, Poly(P) induced osteoblast-like cells from hAT-MSCs.
Poly(P) induces expression of MMP-13 mRNA and activity of MMP-13 in hAT-MSCs
MMP-13 induction by 0.2 mM Poly(P) was assessed using qRT-PCR to measure changes in MMP-13 mRNA expression. The levels of MMP-13 mRNA expression in Poly(P)-treated cells were significantly increased (p < 0.05) at days 3, 5, and 7 of culture ( Figure 3A) . Bone-associated cells also express other MMPs including MMP-1, MMP-2, MMP-3, and MMP-9 (34) (35) (36) . However, we found no significant changes in their expression levels in hAT-MSCs treated with 0.2 mM Poly(P) ( Figure 3B ). Furthermore, MMP-13 activity was significantly increased (p < 0.01) at days 3, 5, and 7 following treatment of hAT-MSCs with Poly(P) for 24 h (Figure 3C ), and no significant differences were found between Poly(P) treatments for 12 or 24 h. MMP-13 activity is precisely regulated at the posttranslational level as a precursor zymogen and by endogenous tissue inhibitors of metalloproteinases (TIMPs) (37) . Although TIMP-2 and TIMP-3 are known to be induced by cytokines (37), we found that TIMP-1-3 proteins were constitutively expressed in all experimental conditions (data not shown).
siRNA silencing of MMP-13 blocks osteogenic differentiation
To examine whether the up-regulation of MMP-13 expression was associated with osteogenic differentiation, hAT-MSCs were transfected with MMP-13 siRNA or a control scrambled siRNA, and then treated with Poly(P) as described above. Transfection of MMP-13 siRNA abrogated the induction of osteogenic ODM: osteogenic differentiation medium. ALP activity was measured in hAT-MSCs treated with or without Poly (P) (B-a,  b) . ALP activity was measured by absorbance at 405 nm and normalized against total protein (**p < 0.01 vs. control). Scale bar: 100μm. (C-a, b) ARS staining of hAT-MSCs treated with Poly(P) (**p < 0.05 vs. control). Scale bar: 100 μm. differentiation markers ALPL, BGLAP, SPP1, OSX, and BSP (p < 0.05, Figure 4A ). Similar changes in the protein levels of each marker were observed in Western blot analyses ( Figure 4B ). Furthermore, MMP-13 siRNA blocked induction of ALP activity in Poly(P)-treated cells (p < 0.01, Figure 5A-a, b) . Similarly, the induction of calcification was markedly suppressed (p < 0.05) by Poly(P) treatment of MMP-13-depleted cells ( Figure 5B-a, b) . Collectively, these data show that expression of MMP-13 is required for osteoblastspecific functions in hAT-MSCs.
Discussion
First, this study is the first report of Poly(P)-induced, MMP-13-mediated responses in the differentiation of hAT-MSCs. We demonstrated that Poly(P)-treated hATMSCs could be a novel in vitro model of bone tissue regeneration. Poly(P) at a concentration of 0.2 mM induced MMP-13 expression in hAT-MSCs ( Figure  2A ) and led to enhanced hAT-MSC differentiation into osteoblast-like cells (Figure 2A-C) , although we were unable to precisely determine how many hAT-MSCs had differentiated. However, phenotypic characterization based on calcification and the levels of ALPL, BGLAP, SPP1, OSX, and BSP suggested that a large proportion of the hAT-MSCs had differentiated into osteoblast-like cells (Figure 2A-a, b) . We have previously demonstrated that the inflammatory cytokine IL-1β or a cytokine mixture induces MMP-3-regulated cell proliferation and suppresses apoptosis in rat DPFCs (38, 39) . Moreover, we previously reported that Poly(P)-induced, MMP-3-mediated proliferation in rat DPFCs is mediated by a Wnt5 signaling cascade (10) . Considering the effect of MMP-13 on osteogenic cell differentiation, the present findings suggest that targeting the MMP-13 gene in these osteogenic cells may have utility in the treatment of periradicular lesions. Additionally, Poly(P)-treated hAT-MSCs could serve as an effective model to explore the pathophysiological mechanisms of wound healing. Furthermore, our current evidence suggests that Poly(P)-induced MMP-13 has previously unrecognized physiological functions in wound healing and bone tissue regeneration.
We showed that Poly(P)-induced cells acquired osteoblast-specific functions following differentiation from hAT-MSCs. Poly(P)-treated hAT-MSCs appeared to be predominantly osteoblasts. A major concern is that we were unable to identify the differentiated cells as osteoblasts because these cells also expressed specific osteoblastic markers including osteocalcin and osteopontin. In conclusion, the current findings presented here support our previous reports (38, 39) and indicate that MMP-13 may have a previously unrecognized physiological function in wound healing and bone tissue regeneration. Because Poly(P) induces MMP-13-regulated hAT-MSC differentiation into osteoblast-like cells, the use of Poly(P) represents a potentially superior therapeutic approach for treatment of periradicular lesions combined with root canal treatment.
